189119-36-6Relevant articles and documents
Combination of a beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity
Jesudason, Cynthia D.,Baker, James E.,Bryant, Robert D.,Fisher, Jack W.,O'Farrell, Libbey S.,Gaich, Gregory A.,He, Minxia M.,Kahl, Steven D.,Kriauciunas, Aidas V.,Heiman, Mark L.,Peters, Mary A.,Rito, Christopher J.,Satterwhite, Julie H.,Tinsley, Frank C.,Trankle, William G.,Shuker, Anthony J.
supporting information; experimental part, p. 583 - 586 (2011/10/02)
We report the novel combination of a selective beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor (sibutramine) with potential for the treatment of obesity. The synthesis and characterization of 6-[4-[2-[[(2S)-3-(9H-carbazol-4-ylo
Carbazolyl-substituted ethanolamines as selective beta -3 agonists
-
, (2008/06/13)
PCT No. PCT/US97/15230 Sec. 371 Date May 4, 1998 Sec. 102(e) Date May 4, 1998 PCT Filed Aug. 28, 1997 PCT Pub. No. WO98/09625 PCT Pub. Date Mar. 12, 1998Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.
